Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.
Identifieur interne : 001498 ( Main/Exploration ); précédent : 001497; suivant : 001499Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.
Auteurs : Erin K. Mccreary [États-Unis] ; Jason M. Pogue [États-Unis]Source :
- Open forum infectious diseases [ 2328-8957 ] ; 2020.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.
DOI: 10.1093/ofid/ofaa105
PubMed: 32284951
PubMed Central: PMC7144823
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.</title><author><name sortKey="Mccreary, Erin K" sort="Mccreary, Erin K" uniqKey="Mccreary E" first="Erin K" last="Mccreary">Erin K. Mccreary</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Pogue, Jason M" sort="Pogue, Jason M" uniqKey="Pogue J" first="Jason M" last="Pogue">Jason M. Pogue</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32284951</idno><idno type="pmid">32284951</idno><idno type="doi">10.1093/ofid/ofaa105</idno><idno type="pmc">PMC7144823</idno><idno type="wicri:Area/Main/Corpus">001986</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001986</idno><idno type="wicri:Area/Main/Curation">001986</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001986</idno><idno type="wicri:Area/Main/Exploration">001986</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.</title><author><name sortKey="Mccreary, Erin K" sort="Mccreary, Erin K" uniqKey="Mccreary E" first="Erin K" last="Mccreary">Erin K. Mccreary</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Pogue, Jason M" sort="Pogue, Jason M" uniqKey="Pogue J" first="Jason M" last="Pogue">Jason M. Pogue</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></analytic><series><title level="j">Open forum infectious diseases</title><idno type="ISSN">2328-8957</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32284951</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.</ArticleTitle><Pagination><MedlinePgn>ofaa105</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofaa105</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.</AbstractText><CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McCreary</LastName><ForeName>Erin K</ForeName><Initials>EK</Initials><Identifier Source="ORCID">0000-0001-6705-2225</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pogue</LastName><ForeName>Jason M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">lopinavir/ritonavir</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32284951</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofaa105</ArticleId><ArticleId IdType="pii">ofaa105</ArticleId><ArticleId IdType="pmc">PMC7144823</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Infect Dis. 2019 Nov 13;69(11):1903-1911</Citation><ArticleIdList><ArticleId IdType="pubmed">30753384</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 1993 Nov;25(5):392-407</Citation><ArticleIdList><ArticleId IdType="pubmed">7904547</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767</Citation><ArticleIdList><ArticleId IdType="pubmed">29161116</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2004 Dec;31(4):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15494274</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Mar;84(5):2511-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20032190</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):64-68</Citation><ArticleIdList><ArticleId IdType="pubmed">32037389</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Mar 5;177:104762</Citation><ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId></ArticleIdList></Reference><Reference><Citation>Trials. 2020 Jan 3;21(1):8</Citation><ArticleIdList><ArticleId IdType="pubmed">31900204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2005 Aug;51(2):98-102</Citation><ArticleIdList><ArticleId IdType="pubmed">16038758</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2019 Sep;47(9):e735-e743</Citation><ArticleIdList><ArticleId IdType="pubmed">31162191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 3;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32125362</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Dec 15;212(12):1904-13</Citation><ArticleIdList><ArticleId IdType="pubmed">26198719</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 29;395(10225):683-684</Citation><ArticleIdList><ArticleId IdType="pubmed">32122468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation><ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation><ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation><ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncologist. 2018 Aug;23(8):943-947</Citation><ArticleIdList><ArticleId IdType="pubmed">29622697</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):e30-e31</Citation><ArticleIdList><ArticleId IdType="pubmed">32032529</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Clin Immunol. 2019 Aug;15(8):813-822</Citation><ArticleIdList><ArticleId IdType="pubmed">31219357</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2020 Mar 13;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference><Reference><Citation>J Korean Med Sci. 2020 Feb 17;35(6):e79</Citation><ArticleIdList><ArticleId IdType="pubmed">32056407</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2017 Mar 9;60(5):1648-1661</Citation><ArticleIdList><ArticleId IdType="pubmed">28124907</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2020 May 1;248:117477</Citation><ArticleIdList><ArticleId IdType="pubmed">32119961</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation><ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2014 Jul;14(7):609-18</Citation><ArticleIdList><ArticleId IdType="pubmed">24852376</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2018 Mar 6;9(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29511076</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):227-30</Citation><ArticleIdList><ArticleId IdType="pubmed">27095301</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2017 Jan 15;215(2):171-174</Citation><ArticleIdList><ArticleId IdType="pubmed">28073857</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Infect Dis. 2020 Mar 10;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32125140</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):385-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21876444</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2018 Aug 1;67(4):533-540</Citation><ArticleIdList><ArticleId IdType="pubmed">29481659</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2019 Dec 12;381(24):2293-2303</Citation><ArticleIdList><ArticleId IdType="pubmed">31774950</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2020 Apr 10;295(15):4773-4779</Citation><ArticleIdList><ArticleId IdType="pubmed">32094225</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):398-400</Citation><ArticleIdList><ArticleId IdType="pubmed">32113510</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Apr 15;70(9):1837-1844</Citation><ArticleIdList><ArticleId IdType="pubmed">31925415</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 May;92(5):461-463</Citation><ArticleIdList><ArticleId IdType="pubmed">32073161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Drug Monit. 2011 Oct;33(5):573-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21912331</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 7;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2016 Mar 17;531(7594):381-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26934220</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation><ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Apr;10(4):581-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15200845</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Mar 18;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638</Citation><ArticleIdList><ArticleId IdType="pubmed">30592986</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18852458</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation><ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar 4;:105932</Citation><ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2016 Jul 30;388(10043):498-503</Citation><ArticleIdList><ArticleId IdType="pubmed">27209148</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2018 Feb;150:155-163</Citation><ArticleIdList><ArticleId IdType="pubmed">29289665</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2006 May 4;49(9):2845-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16640347</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Control Hosp Epidemiol. 2020 Mar 13;:1-2</Citation><ArticleIdList><ArticleId IdType="pubmed">32167442</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2006 Jun;129(6):1441-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16778260</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li><li>Pennsylvanie</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Mccreary, Erin K" sort="Mccreary, Erin K" uniqKey="Mccreary E" first="Erin K" last="Mccreary">Erin K. Mccreary</name></region><name sortKey="Pogue, Jason M" sort="Pogue, Jason M" uniqKey="Pogue J" first="Jason M" last="Pogue">Jason M. Pogue</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001498 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001498 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32284951
|texte= Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32284951" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |